Advertisement

Journal of Medical Toxicology

, Volume 10, Issue 4, pp 431–434 | Cite as

Expanding Access to Naloxone in the United States

  • Suzanne Doyon
  • Steven E. Aks
  • Scott Schaeffer
Position Statement

Background

Drug overdose deaths have increased steadily in the USA since 1979. During the past three decades, drug overdose deaths have tripled [1, 2]. In 2008, the number of unintentional poisoning deaths exceeded the number of motor vehicle deaths for the first time [1]. Of the 38,329 drug overdose deaths in the USA in 2010, 22,134 (60 %) were related to pharmaceuticals, with 75 % of those deaths involving prescription opioid analgesics [3]. Concomitantly, heroin deaths have risen 55 % between 2000 and 2010 [4]. Deaths from use of fentanyl- or acetyl fentanyl-laced heroin were reported in multiple states in 2013 [5, 6, 7]. In 2012, the Centers for Disease Control characterized opioid overdose deaths as an epidemic [8]. Most of these deaths are preventable.

In overdose, opioids, including morphine, oxycodone, hydrocodone, methadone, and fentanyl, cause respiratory depression that can lead to hypoxia and, if untreated, death. The exact neuronal mechanisms by which opioids depress...

Keywords

Naloxone Opiate Opioid Bystander naloxone Overdose 

Notes

Disclaimer

While individual practitioners may differ, these are the positions of the ACMT, AACT, and AAPCC at the time written, after review of the issue and pertinent literature.

References

  1. 1.
    Warner M, Hui L, Makuc DL, Anderson RN et al (2011) Drug poisoning deaths in the United States, 1980–2008. NCHS data brief no 81. National Center for Health Statistics, HyattsvilleGoogle Scholar
  2. 2.
    Wheeler E, Davidson PJ, Jones S et al (2012) Community-based opioid overdose prevention programs providing naloxone-United States, 2010. MMWR 61(06):101–5Google Scholar
  3. 3.
    Jones CM, Mack KA, Paulozzi LJ (2013) Pharmaceutical overdose deaths, United Sates 2010. JAMA 309:657–9PubMedCrossRefGoogle Scholar
  4. 4.
    Heroin-related deaths in the US. Blog for the National Center for Health Statistics http://nchstats.com/2014/02/05/heroin-related-deaths-in-the-us/. Accessed April 11 2014.
  5. 5.
    Maryland Department of Health and Mental Hygiene http://dhmh.maryland.gov/newsroom1/Pages/DHMH-Warns-of-Potent-and-Deadly-Drug-Combination.aspx Accessed April 2014.
  6. 6.
    Ogilvie L, Stanley C, Lewis L et al (2013) Notes from the field: acetyl fentanyl overdose fatalities-Rhode Island March–May 2013. MMWR 62(34):703–4Google Scholar
  7. 7.
    Philadelphia Department of Public Health. Overdoses from tainted opioids recommendations for management. Health Advisory 2014; https://hip.phila.gov/xv/Portals/0/HIP/Health_Alerts/2014/PDPH-HAN_Advisory_2_TaintedOpioidOverdoses_012814.pdf Accessed April 2014.
  8. 8.
    Centers for Disease Control and Prevention (2012) CDC Grand Rounds: prescription drug overdoses—a U.S. epidemic. MMWR 61(01):10–3Google Scholar
  9. 9.
    Pattinson KT (2008) Opioids and the control of respiration. Br J Anaesth 100(6):747–58PubMedCrossRefGoogle Scholar
  10. 10.
    Lalley PM (2008) Opioidergic and dopaminergic modulation of respiration. Respir Physiol Neurobiol 164:160–7PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Lalley PM (2003) Mu-opioid receptor agonist effects on medullary respiratory neurons in the cat: evidence for involvement in certain types of ventilatory disturbances. Am J Physiol Regul Integr Comp Physiol 285:R1287–304PubMedGoogle Scholar
  12. 12.
    Wermeling DP (2013) A response to the opioid overdose epidemic: naloxone nasal spray. Drug Deliv and Transl Res 3:63–74CrossRefGoogle Scholar
  13. 13.
    Wolfe TR, Braude DA (2010) Intranasal medication delivery for children: a brief review and update. Pediatrics 126:532–7PubMedCrossRefGoogle Scholar
  14. 14.
    Sporer KA, Kral AH (2007) Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med 49(2):172–7PubMedCrossRefGoogle Scholar
  15. 15.
    Piper TM, Stancliff S, Rudenstine S et al (2008) Evaluation of a naloxone distribution administration program in New York City. Subs Abuse Misuse 43:858–70CrossRefGoogle Scholar
  16. 16.
    Enteen L, Bauer J, McLean R et al (2010) Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health 87(6):931–41PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Dietze P, Cantwell K, Burgess S (2002) Bystander resuscitation attempts at heroin overdose: does it improve outcomes? Drug Alcohol Depend 67:213–8PubMedCrossRefGoogle Scholar
  18. 18.
    Doe-Simkins M, Quinn E, Xuan Z et al (2014) Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective study. BMC Public Health 14(297):1–11Google Scholar
  19. 19.
    Loimer N, Hofmann P, Choudhry HR (1992) Nasal administration of naloxone for detection of opiate dependence. J Psychiatr Res 26(1):39–43PubMedCrossRefGoogle Scholar
  20. 20.
    Loimer N, Hofmann P, Choudhry HR (1994) Nasal administration of naloxone is as effective as the intravenous route in opiate addicts. Int J Addict 29(6):819–27PubMedGoogle Scholar
  21. 21.
    Kelly AM, Koutsogiannis Z (2002) Intranasal naloxone for life-threatening opioid overdose. Emerg Med J 19(4):375PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Seal KH, Thawley R, Gee L et al (2005) Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health 82:303–11PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Maxwell S, Bigg D, Stanczykiewicz K et al (2006) Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis 25(3):89–96PubMedCrossRefGoogle Scholar
  24. 24.
    Tobin KA, Sherman SG, Beilenson P et al (2009) Evaluation of the Staying Alive programme: training injection drug users to properly administer naloxone and save lives. Int J Drug Policy 20:131–6PubMedCrossRefGoogle Scholar
  25. 25.
    Doe-Simkins M, Walley AY, Epstein A et al (2009) Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 99(5):788–90PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Benett AS, Bell A, Tomedi L et al (2011) Characteristics of an overdose prevention response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania. J Urban Health 88(6):1020–30CrossRefGoogle Scholar
  27. 27.
    Walley A, Xuan Z, Hackman HH et al (2013) Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 346:f174, 1:12PubMedCrossRefGoogle Scholar
  28. 28.
    Walley AY, Doe-Simkins M, Quinn E et al (2013) Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat 44:241–7PubMedCrossRefGoogle Scholar
  29. 29.
    Wagner KD, Valente TW, Casanova M et al (2010) Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Int J Drug Policy 21(3):186–93PubMedCrossRefGoogle Scholar
  30. 30.
    Su A, Brason FW, Sanford C et al (2011) Project Lazarus: community-based overdose prevention in rural North Carolina. Pain Med 12:S77–85CrossRefGoogle Scholar
  31. 31.
    Buajordet I, Naess AC, Jacobsen D et al (2004) Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Euro J Emerg Med 11:19–23CrossRefGoogle Scholar
  32. 32.
    Sporer KA (1999) Acute heroin overdose. Ann Intern Med 130(7):584–90PubMedCrossRefGoogle Scholar
  33. 33.
    Merigian KS (1993) Cocaine-induced ventricular arrhythmias and rapid atrial fibrillation temporarily related to naloxone administration. Am J Emerg Med 11:96–7PubMedCrossRefGoogle Scholar
  34. 34.
    Osterwalder JJ (1996) Naloxone—for intoxications with intravenous heroin and heroin mixtures—harmless or hazardous? A prospective clinical study. J Toxicol Clin Toxicol 34(4):409–16PubMedCrossRefGoogle Scholar
  35. 35.
    Kim D, Irwin KS, Koshnood K (2009) Expanded access to naloxone: options for critical response to the epidemic of opioid overdose mortality. Am J Public Health 99(3):402–7PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Wampler DA, Molina K, McManus J, Laws P, Manifold A (2011) No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose. Prehosp Emerg Care 15:320–4PubMedCrossRefGoogle Scholar
  37. 37.
    Vilke GM, Sloane C, Smith AM et al (2003) Assessment for deaths in out-of-hospital heroin overdoses patients treated with naloxone who refuse transport. Acad Emerg Med 10(8):893–6PubMedCrossRefGoogle Scholar
  38. 38.
    Leece P, Orkin A (2013) Opioid overdose fatality prevention (letter). JAMA 309(9):873–4PubMedCrossRefGoogle Scholar
  39. 39.
    Morris J (2000) Defining the precautionary principle. In: rethinking risk and the precautionary principle. New York: Butterworth-Heinemann, 1–21.Google Scholar
  40. 40.
    Goklany IM (2002) From precautionary principle to risk-risk analysis. Nat Biotechnol 20:1075PubMedCrossRefGoogle Scholar
  41. 41.
    Belestky L, Rich JD, Walley AY (2013) Opioid overdose fatality prevention (reply to letter). JAMA 309(9):874CrossRefGoogle Scholar
  42. 42.
    Strang J, Powis B, Best D et al (1999) Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction 94:199–204PubMedCrossRefGoogle Scholar
  43. 43.
    Dettmer K, Saunders B, Strang J (2001) Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. BMJ 322(7291):895–6PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Tracy M, Piper TM, Ompad D et al (2005) Circumstances of witnessed drug overdose in New York City: implications for intervention. Drug Alcohol Depend 79:181–90PubMedCrossRefGoogle Scholar
  45. 45.
    Lagu T, Anderson BJ, Stein M (2006) Overdoses among friends: drug users-are willing to administer naloxone to others. J Subst Abuse Treat 30:129–33PubMedCrossRefGoogle Scholar

Copyright information

© American College of Medical Toxicology 2014

Authors and Affiliations

  • Suzanne Doyon
    • 1
  • Steven E. Aks
    • 2
  • Scott Schaeffer
    • 3
  1. 1.American Academy of Clinical ToxicologyMcLeanUSA
  2. 2.American College of Medical ToxicologyPhoenixUSA
  3. 3.American Association of Poison Control CentersAlexandriaUSA

Personalised recommendations